Patents by Inventor Michalis Nicolaou

Michalis Nicolaou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Target-enriched multiplexed parallel analysis for assessment of risk for genetic conditions
    Patent number: 11879157
    Abstract: The invention provides methods for assessment of risk for genetic conditions using target-enriched multiplexed parallel analysis, for example fetal risk for genetic conditions in prenatal testing. The methods of the invention utilize Target Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods of the disclosure can be used to determine carrier status of inheritable genetic abnormalities associated with genetic conditions and from this information the fetal risk of inheriting the genetic condition can be determined. Kits for carrying out the methods of the invention are also provided.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: January 23, 2024
    Assignee: NIPD GENETICS PUBLIC COMPANY LIMITED
    Inventors: George Koumbaris, Marios Ioannides, Kyriakos Tsangaras, Charalambos Loizides, Michalis Nicolaou, Skevi Kyriakou, Philippos Patsalis, Elena Kypri
  • TARGET-ENRICHED MULTIPLEXED PARALLEL ANALYSIS FOR ASSESSMENT OF RISK FOR GENETIC CONDITIONS
    Publication number: 20210147937
    Abstract: The invention provides methods for assessment of risk for genetic conditions using target-enriched multiplexed parallel analysis, for example fetal risk for genetic conditions in prenatal testing. The methods of the invention utilize Target Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods of the disclosure can be used to determine carrier status of inheritable genetic abnormalities associated with genetic conditions and from this information the fetal risk of inheriting the genetic condition can be determined. Kits for carrying out the methods of the invention are also provided.
    Type: Application
    Filed: July 6, 2018
    Publication date: May 20, 2021
    Inventors: George Koumbaris, Marios loannides, Kyriakos Tsangaras, Charalambos Loizides, Michalis Nicolaou, Skevi Kyriakou, Philippos Patsalis, Elena Kypri
  • GLP-1 receptor agonist bioassay
    Patent number: 8603761
    Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: December 10, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Michalis Nicolaou, Frederick Charles Bancroft, John Patrick Herich, Aung Naing Lwin, Swati Gupta
  • TREATMENT OF DISEASES MODULATED BY A H4 RECEPTOR AGONIST
    Publication number: 20130059878
    Abstract: The invention provides a method for the treatment of H4R modulated diseases and/or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 18, 2012
    Publication date: March 7, 2013
    Inventors: Emile Loria, Michalis Nicolaou, Gaetan Terrasse, Yves Trehin
  • GLP-1 receptor agonist bioassays
    Patent number: 8329419
    Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: December 11, 2012
    Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
    Inventors: Michalis Nicolaou, Frederick Charles Bancroft, John Patrick Herich, Swati Gupta, Aung Naing Lwin
  • TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBATORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS
    Publication number: 20120295933
    Abstract: The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.
    Type: Application
    Filed: May 18, 2012
    Publication date: November 22, 2012
    Inventors: Emile Loria, Michalis Nicolaou, Gaetan Terrasse, Yves Trehin
  • Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
    Patent number: 8207292
    Abstract: The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: June 26, 2012
    Inventors: Michalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin
  • Treatment of diseases modulated by a H4 receptor agonist
    Patent number: 8207188
    Abstract: The invention provides a method for the treatment of H4R modulated diseases and/or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: June 26, 2012
    Inventors: Michalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin
  • PURE ISOMERS OF TRITOQUALINE
    Publication number: 20120101120
    Abstract: The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. 2 and FIG. 3.
    Type: Application
    Filed: August 24, 2011
    Publication date: April 26, 2012
    Inventors: Michalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin
  • GLP-1 RECEPTOR AGONIST BIOASSAYS
    Publication number: 20110097751
    Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
    Type: Application
    Filed: May 15, 2009
    Publication date: April 28, 2011
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Michalis Nicolaou, Frederick Charles Bancroft, John Patrick Herich, Aung Naing Lwin, Swati Gupta
  • TREATMENT OF DISEASES MODULATED BY A H4 RECEPTOR AGONIST
    Publication number: 20100144718
    Abstract: The invention provides a method for the treatment of H4R modulated diseases and/or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 17, 2009
    Publication date: June 10, 2010
    Inventors: Michalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin
  • Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
    Publication number: 20080207530
    Abstract: The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.
    Type: Application
    Filed: February 12, 2008
    Publication date: August 28, 2008
    Inventors: Michalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin
  • Pure isomers of tritoqualine
    Publication number: 20070238750
    Abstract: The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. 2 and FIG. 3.
    Type: Application
    Filed: April 9, 2007
    Publication date: October 11, 2007
    Inventors: Michalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin